| 11/06/2026 3:32 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/05/2026 3:31 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/05/2026 6:12 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/04/2026 3:58 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/04/2026 3:56 PM | Taddese Menassie (1848805) Reporting Xeris Biopharma (1867096) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 11/04/2026 3:56 PM | Taddese Menassie (1848805) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/04/2026 3:57 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/04/2026 3:57 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/02/2026 3:39 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/02/2026 7:05 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2026 11:35 AM | VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by Xeris Biopharma (1867096) Subject | Form SCHEDULE 13G/A | |
Get the Latest News and Ratings for XERS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter.
|
| 10/14/2026 6:08 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/29/2026 3:59 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/28/2026 3:19 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/09/2026 7:33 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/01/2026 5:20 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/01/2026 5:21 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/01/2026 5:21 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/21/2026 3:15 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/12/2026 3:44 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/06/2026 6:12 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/04/2026 4:30 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/04/2026 4:16 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/17/2026 3:20 PM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/07/2026 4:11 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/07/2026 3:37 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 4:59 PM | KREHER NERISSA (1741850) Reporting Xeris Biopharma (1867096) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 07/02/2026 5:01 PM | KREHER NERISSA (1741850) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 3:51 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/01/2026 3:21 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 3:06 PM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/11/2026 6:16 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/05/2026 5:39 PM | Kong Garheng (1435183) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 5:29 PM | PERSKY MARLA (1270354) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 5:16 PM | Brady James Aloysius (1916987) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 5:17 PM | JOHNSON JOHN (1410781) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 5:18 PM | BORMANN-KENNEDY BARBARA-JEAN ANNE (1635065) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 5:18 PM | HALKUFF DAWN (1743658) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/04/2026 3:32 PM | BORMANN-KENNEDY BARBARA-JEAN ANNE (1635065) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/04/2026 3:33 PM | JOHNSON JOHN (1410781) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/04/2026 3:33 PM | HALKUFF DAWN (1743658) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Your Copy is on Hold (Claim it now) (Ad) James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play.
He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60.
Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date. Claim your copy of James Altucher's new Elon Musk report today. |
| 06/02/2026 5:05 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 6:15 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/01/2026 4:50 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 4:08 PM | Xeris Biopharma (1867096) Filer | Form DEF 14A | |
| 04/23/2026 4:08 PM | Xeris Biopharma (1867096) Filer | Form DEFA14A | |
| 04/23/2026 4:09 PM | Xeris Biopharma (1867096) Filer | Form ARS | |
| 04/21/2026 3:27 PM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/03/2026 4:45 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 4:54 PM | Brady James Aloysius (1916987) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/16/2026 5:11 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/05/2026 6:18 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 4:28 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 6:08 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/25/2026 5:03 PM | Nguyen Anh Tu (2058704) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/02/2026 5:11 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/02/2026 5:11 PM | Nguyen Anh Tu (2058704) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/02/2026 5:12 PM | Pieper Steven (1875714) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/02/2026 5:12 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/02/2026 5:13 PM | Shannon John Patrick Jr (1553595) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/30/2026 1:43 PM | VANGUARD GROUP INC (102909) Filed by Xeris Biopharma (1867096) Subject | Form SCHEDULE 13G/A | |
| 01/09/2026 4:34 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/08/2026 3:22 PM | McCulloch Kevin (2031695) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 01/08/2026 6:18 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 5:14 PM | Shannon John Patrick Jr (1553595) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 5:01 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 5:15 PM | JOHNSON JOHN (1410781) Reporting Xeris Biopharma (1867096) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/19/2025 4:17 PM | JOHNSON JOHN (1410781) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/15/2025 4:24 PM | BORMANN-KENNEDY BARBARA-JEAN ANNE (1635065) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/02/2025 4:14 PM | Hecht Beth (1652410) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 6:00 AM | Xeris Biopharma (1867096) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/17/2025 4:58 PM | Shannon John Patrick Jr (1553595) Reporting Xeris Biopharma (1867096) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |